| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23041 |
| Drug | Imlifidase |
| Brand | Idefirix® |
| Indication | For desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. |
| Assessment Process | |
| Rapid review commissioned | 19/07/2023 |
| Rapid review completed | 01/08/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imlifidase compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 30/08/2023 |
| Pre-submission consultation with Applicant | 21/11/2023 |
| Full submission received from Applicant | 22/04/2024 |
| Preliminary review sent to Applicant | 16/09/2024 |
| NCPE assessment re-commenced | 09/10/2024 |
| Factual accuracy sent to Applicant | 21/11/2024 |
| NCPE assessment re-commenced | 28/11/2024 |
| NCPE assessment completed | 28/11/2024 |
| NCPE assessment outcome | The NCPE recommends that imlifidase be considered for reimbursement*. |
*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
